Data / Drug companies / Fosun Pharma USA Inc.
Fosun Pharma USA Inc.: 55 products in the FDA NDC directory, labeler code 72266
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Fosun Pharma USA Inc. (labeler code 72266) lists 55 products in the FDA National Drug Code Directory, covering 36 finished drugs by generic name. By type: 55 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 29, 2026.
The request: Watch Fosun Pharma USA Inc. (FDA labeler code 72266): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72266
- Products in commercial distribution
- 55
- Packages
- 58
- Finished drugs by generic name
- 36
- Prescription products
- 55
- Over the counter products
- 0
- Controlled substance products
- Schedule V 1
- Flagged as original packager
- 55 of 55 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- March 18, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 53 | 96.4% |
| New drug applications (NDA) | 2 | 3.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 55 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 14 | 25.5% |
| Injection, powder, lyophilized, for solution | 13 | 23.6% |
| Injection | 11 | 20% |
| Solution/ drops | 6 | 10.9% |
| Tablet, extended release | 4 | 7.3% |
| Solution | 4 | 7.3% |
| Solution, gel forming / drops | 2 | 3.6% |
| Kit | 1 | 1.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 72266-269 | Injection, solution | Generic drugs (ANDA) | July 29, 2026 |
| Sugammadex | 72266-268 | Injection, solution | Generic drugs (ANDA) | July 29, 2026 |
| Guanfacine | 72266-258 | Tablet, extended release | Generic drugs (ANDA) | April 3, 2026 |
| Bupivacaine Hydrochloride | 72266-264 | Injection, solution | Generic drugs (ANDA) | February 6, 2026 |
| Bupivacaine Hydrochloride | 72266-263 | Injection, solution | Generic drugs (ANDA) | February 6, 2026 |
| Thiamine Hydrochloride | 72266-260 | Injection, solution | Generic drugs (ANDA) | February 6, 2026 |
| Bimatoprost | 72266-241 | Solution/ drops | Generic drugs (ANDA) | November 30, 2025 |
| Guanfacine | 72266-257 | Tablet, extended release | Generic drugs (ANDA) | October 1, 2025 |
| Guanfacine | 72266-256 | Tablet, extended release | Generic drugs (ANDA) | October 1, 2025 |
| Guanfacine | 72266-255 | Tablet, extended release | Generic drugs (ANDA) | October 1, 2025 |
| Levothyroxine Sodium | 72266-261 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 16, 2025 |
| Arformoterol tartrate | 72266-259 | Solution | Generic drugs (ANDA) | April 8, 2025 |
| Polymyxin b | 72266-249 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 31, 2023 |
| Cisplatin | 72266-253 | Injection, solution | Generic drugs (ANDA) | August 11, 2023 |
| Cisplatin | 72266-252 | Injection, solution | Generic drugs (ANDA) | August 11, 2023 |
| Ketorolac tromethamine | 72266-234 | Injection, solution | Generic drugs (ANDA) | June 23, 2023 |
| Ketorolac tromethamine | 72266-119 | Injection, solution | Generic drugs (ANDA) | June 23, 2023 |
| Ketorolac tromethamine | 72266-118 | Injection, solution | Generic drugs (ANDA) | June 23, 2023 |
| Calcitriol | 72266-251 | Injection | Generic drugs (ANDA) | June 20, 2023 |
| Zoledronic acid | 72266-152 | Injection | Generic drugs (ANDA) | June 12, 2023 |
| Prochlorperazine Edisylate | 72266-204 | Injection | Generic drugs (ANDA) | May 1, 2023 |
| Doxycycline | 72266-237 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 12, 2023 |
| Timolol Maleate Ophthalmic Gel Forming Solution | 72266-200 | Solution, gel forming / drops | Generic drugs (ANDA) | March 15, 2023 |
| Dorzolamide Hydrochloride | 72266-197 | Solution | Generic drugs (ANDA) | January 23, 2023 |
| Sincalide | 72266-248 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | January 9, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.